Tue, Oct 21, 2014, 12:20 AM EDT - U.S. Markets open in 9 hrs 10 mins

Recent

% | $
Quotes you view appear here for quick access.

Cardica Inc. Message Board

  • maphere maphere Aug 9, 2013 5:07 PM Flag

    Future Funding...

    1. Dilutive financing (another 15Mn)?
    2. Development deal with ISRG? ISRG needs to broaden procedures as placing new robots gets tougher. CRDC is the one they would go to for assistance.
    3. Sell C-Port / Pas-Port?
    4. Buyout?

    They have money to get the microcutter through the FDA approval process but empty handed after that.

    Thoughts?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • There was no talk of ISRG at the CC, was there?
      I think they have there own stapler.
      C Port / Pas port should be no longer be a focus.
      Perhaps they should work on the Xpress 30 and see it not fail in the in vitro tests.

      • 1 Reply to berniehousen_thethird
      • From a post Oct. 12, 2012 regarding ISRG stapler:
        _________________________

        I believe it's call the EndoWrist Stapler, here is some info from a PPT:

        Articulation: 60º pitch, 25ºyaw
        45 mm jaw (white, green & blue re-loads)
        13 mm diameter instrument
        _________________

        Xchange = 5mm and 80 degree articulation

        ________________________

        ISRG comments from their last cc:

        As we enter new surgical markets and drive into new product arenas, we continue to invest in building our team. In expanding partnerships and in acquiring those technologies, that can make a difference to robotic surgery.

        Stapler will really ultimately be a family of products, kind of a platform. And that will come out in sequential releases. So there is a set of releases and products that make sense for colorectal surgery, a different set that makes sense for thoracic surgery and a different set that might make sense for bariatric surgery in the future

    • Map, if were up to me I'd try to maximize EU sales with current distributors and Century in Japan. Have a US Distribution through AMC as the would be best partner. AMC already has knowledge of the largest 5mm trocar users, are in need of a stapler as the Eithicon bundling agreement runs out in a year and will be motivated to take share from the 2 behemoths. I'd EU mark the exchange 45 and possible express. As part of deal with AMC, I'd also contract manufacture with them as that is their real expertise.

      Sentiment: Strong Buy

      • 2 Replies to biotechbeagle
      • andersongordon@ymail.com andersongordon Aug 12, 2013 1:20 PM Flag

        Bio:
        It does sound like a good plan. Send it to Cardica just as it is. The negotiations with AMC should be structured to provide all the funding needed to complete the stable of micro-cutter products both cartridge and the continuous feed options. It will be to AMC's advantage to increase both scope and scale of the cutter-staplers. Their incentive should be tied to quality and cost of the manufacturing. The marketing aspects should be structured so that AMC receives increasing incentives to penetrate the market. Cardica's incentive should be to expedite the family development and regulatory approval. A secondary incentive should be tied to clinical efficacy (clinical studies, papers, presentations etc.). The structure of the eventual agreement could prove to be the most important aspect of success going forward.

        "Go CRDC Go"

        GSA

      • I agree BioBeagle! Sounds like a good plan! ISRG will come aboard sooner than people expect.
        That and AMC could be a funding source for further capital needed to continue development
        of total MicroCutter Line of Products. Go CRDC Go!

 
CRDC
0.970.00(0.00%)Oct 20 3:58 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.